Navigation Links
Efficacy Advantages and Long-Term Cost Savings Will Help Optimize Reimbursement in the EU5 for Type 2 Diabetes Agents
Date:8/26/2013

BURLINGTON, Mass., Aug. 26, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that as the health technology assessment bar rises sharply across the EU5 (France, Germany, Italy, Spain and the United Kingdom), interviewed payers seek robust efficacy advantages over the right comparators and clear demonstration of potential for downstream cost savings in exchange for optimal reimbursement of type 2 diabetes therapies. As type 2 diabetes becomes increasingly prevalent in Western markets, the cost of related complications and comorbidities weighs heavily on tightening EU5 healthcare budgets. Payers report that novel agents that delay disease progression and show positive weight loss and cardiovascular outcomes data, ideally with detailed pharmacoeconomic analyses, will secure favorable market access conditions long term.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The new European Physician and Payer Forum report entitled Market Access Challenges Facing Newly Launched and Emerging Type 2 Diabetes Agents in the EU5: Physician Prescribing Perspectives and Payer Insights finds that at least three-quarters of surveyed EU5 endocrinologists, diabetologists and general practitioners (GPs) believe that, despite market crowding, unmet need remains for the DPP-IV inhibitor drug class, while at least two-thirds think likewise for the GLP-1 receptor agonists. Key unmet needs highlighted for the DPP-IV inhibitors include better reduction in HbA1c, and confirmation of disease-modifying effect, while—in addition to injection-free admin
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
2. MedQIA unique CAD algorithm for Quantitation of lung involvement in diffuse lung disease used as treatment efficacy end point in study to be reported at the ERS Annual Conference in Vienna, Austria: September 1-5, 2012
3. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
4. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
5. Optimization of Comparative Efficacy Trials
6. JAMA Study Demonstrates Efficacy of Life Technologies Lung Cancer Test in Detecting Early Metastases, Supports Screening for Lung Cancer
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
9. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
10. Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results
11. Data Demonstrating the Safety and Efficacy of Chimerixs Antiviral CMX001 Presented at BMT Tandem Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today it has completed enrollment ... Data Review Committee (DRC) earlier this year, into ... is a first-in-class innate defense regulator (IDR) and ...
(Date:8/31/2015)... STAMFORD, Conn. , Aug. 31, 2015 /PRNewswire/ ... Ltd., and Purdue Pharma L.P. announced today that they ... development and commercialization of Eisai,s clinical candidate lemborexant (development ... III clinical development for the treatment of insomnia. ... and Purdue Pharma will share the costs of lemborexant ...
(Date:8/31/2015)... 31, 2015 Research and Markets ( ... "Prescription Pain Drugs - Including Opioid, Anticonvulsant, ... Markets, Competitors and Opportunities: 2015 - 2020 Analysis ... Pain is defined as an unpleasant ... potential tissue damage. At some point, everyone experiences ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
(Date:8/31/2015)... TN (PRWEB) , ... August 31, 2015 , ... ... urgent care and accessible primary care, is enhancing its existing presence in Tennessee ... in Knoxville. The location is the company’s second in Knoxville, sixteenth in Tennessee, ...
(Date:8/31/2015)... PA (PRWEB) , ... August 31, 2015 , ... ... than their peers may be at a greater risk for injury, potentially because ... behaviors, a University of Pittsburgh Graduate School of Public Health analysis discovered. ...
(Date:8/31/2015)... ... August 31, 2015 , ... Castle Dermatology Institute now ... Dr. Pedram Ghasri is a graduate of the University of California, Los Angeles. He ... studies at the University of California, Irvine Medical School. As a nationally recognized Regents ...
(Date:8/31/2015)... ... 2015 , ... The German soccer league (DFL Digital Sports) ... make website updates quicker and more flexible. The company's CMS solution FirstSpirit is ... German equivalent of the U.S. Soccer Federation) more modern, exciting and interactive for ...
(Date:8/31/2015)... ... August 31, 2015 , ... "While working as an ... effectively deliver oxygen with a lower risk of failure," explained an inventor, from ... the Adam Device." , The Adam Device offers a quick, effective and predictable ...
Breaking Medicine News(10 mins):Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:On the Ball with FirstSpirit: German Soccer League (DFL Digital Sports) Opts for e-Spirit’s CMS 2Health News:InventHelp® Client's Invents Medical Device to Restore Respiratory Function (BGF-905) 2
... Operations of Grady Memorial Hospital, ATLANTA, Dec. 13 ... $100,000 to the Henry W. Grady Health System,Foundation. The ... Grady Memorial,Hospital, which plays a pivotal role in bringing ... AMERIGROUP Foundation is affiliated with AMERIGROUP Community Care,of Georgia, ...
... targeted treatments for leukemia, bone marrow transplants , THURSDAY, ... human blood cells has been identified by Stanford University ... treatments for blood cancers and other blood diseases. , ... the initial offspring of a blood-forming stem cell in ...
... DALLAS and LONDON, Dec. 13 U.S. ... first network focused on prevention in the,United ... it has signed a letter of intent ... preventive medicine businesses in the United Kingdom.,iHealth ...
... and 14 Walkouts at Thirteen ... Facilities, ... facilities throughout Northern California are,preparing for their second strike against the healthcare ... patient care and,patient safety. Sutter has threatened a lockout at the majority ...
... Speaker Nancy Pelosi,Majority Leader Steny Hoyer, Majority Whip James ... news conference late this afternoon in,the Capitol on the ... the bill. Below are the Speaker,s opening remarks:, ... the President,will veto the SCHIP bill. Once again, he ...
... creams, supplements and plastic surgery to look younger if they ... , A study of 297 women aged from 27 to ... with special diets, vitamins, creams, Botox or plastic surgery if ... look significantly younger. , The researchers, Professor Brett Martin ...
Cached Medicine News:Health News:AMERIGROUP Foundation Awards $100,000 to Grady Health System Foundation in Atlanta 2Health News:AMERIGROUP Foundation Awards $100,000 to Grady Health System Foundation in Atlanta 3Health News:U.S. Preventive Medicine to Expand into England with iHealth UK Ltd. 2Health News:U.S. Preventive Medicine to Expand into England with iHealth UK Ltd. 3Health News:5,000 Sutter Nurses Prepare for Second Strike Against Chain 2Health News:5,000 Sutter Nurses Prepare for Second Strike Against Chain 3Health News:Pelosi on Bush Veto of SCHIP: 'Democrats Will Not Rest Until 10 Million Children Have Access to Health Care' 2Health News:Women persist in plastic surgery treatments that are not working, research says 2
... Suture™ POLY GIA™ 75-.060 single use ... rows of LACTOMER™ absorbable copolymer staples ... the two, double rows., ,The ... use surgical stapler has application in ...
... Single Use Loading Units ... with ILA™ 75 (Single Use ... ,INDICATIONS The ILA™ 75 ... designed for use in the ...
... Reloadable Staplers and the SGIA™ Knifeless ... pediatric and thoracic surgical procedures for ... , ,The Auto Suture™ GIA™ ... Stapler have application in abdominal, gynecological, ...
... anastomotic staplers available in four sizes to ... diameter. The staplers permit tissue attachment to ... and ease of use. The instruments allow ... adjusting the height of the closed staple. ...
Medicine Products: